Released Nov 16, 2026, before the open
10-Q filed Nov 16, 2026, 47 days after period end · 0001789769-26-000067
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$4.23M | -$13.59M | -$23.02M | -$67.43M |
| EPS Diluted | -$0.62 | -$2.01 | -$3.54 | -$10.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Instil Bio, Inc. · CIK 1789769 · Engraved from SEC EDGAR
Instil Bio reported a net loss of $4.2 million and $13.0 million for the three and nine months ended September 30, 2026, compared to $13.6 million and $63.5 million, as corrected, for 2025.¶1
Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled $67.1 million as of September 30, 2026, which Instil expects will fund its operating plan through 2027.¶2¶3
Net loss per share, basic and diluted, was $0.62 and $1.92 for the three and nine months ended September 30, 2026, compared to $2.01 and $9.58, as corrected, for 2025.¶1
Research and development expenses were $0.2 million and $1.2 million for the three and nine months ended September 30, 2026, compared to $9.1 million and $21.2 million for 2025.¶4